中文(繁體)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Annals of Pharmacotherapy 2011-Mar

Evaluation of contraindicated drug-drug interaction alerts in a hospital setting.

只有註冊用戶可以翻譯文章
登陸註冊
鏈接已保存到剪貼板
Randy C Hatton
Amy F Rosenberg
Candice T Morris
Russell P McKelvey
James R Lewis

關鍵詞

抽象

BACKGROUND

Risks associated with contraindicated drug-drug interaction alerts (CDDIAs) should always outweigh benefits. Misclassified CDDIAs should be eliminated.

OBJECTIVE

To review CDDIAs and determine if they are contraindicated according to Food and Drug Administration-approved product labeling and if there are circumstances in which contraindicated interactions are acceptable.

METHODS

A cross-sectional observational and quality improvement study was conducted over two 1-year periods. The 20 most common CDDIAs from May 2007 to May 2008 and all CDDIAs from April 2008 to April 2009 were collected at a large teaching hospital. Horizon Meds Manager used First DataBank as the knowledge base for decision support. Interactions were deemed truly contraindicated if listed in the contraindications section of the labeling of at least one of the interacting drugs. Alerts were grouped by drug and pharmacologic class to evaluate the evidence supporting the relevance of these interactions. An expert panel determined when an alert was misclassified. A medical advisory committee determined whether a contraindicated drug-drug combination was acceptable.

RESULTS

Twelve (60%) of the most common 20 contraindicated interaction pairs from 2007 to 2008 were inappropriately classified. Half of the alerts were not truly contraindicated. The 8 truly contraindicated drug-drug pairs were ketorolac and other nonsteroidal antiinflammatory drugs or oral solid potassium products and anticholinergics. Half of these interactions were subsequently deemed acceptable under specific circumstances. Similar results were found in the second year, with only 55.1% of all CDDIAs being truly contraindicated despite eliminating some of the alerts that were misclassified in the first year. Nearly three fourths of legitimate CDDIAs were deemed acceptable under specific circumstances.

CONCLUSIONS

Most contraindicated drug-drug interaction alerts from a commercial knowledge base were inappropriately categorized and could be downgraded. Some contraindicated drug combinations are permissible under specific circumstances. Alerts suggesting that certain drugs should never be used together, but their use together is sometimes acceptable, contribute to alert fatigue.

加入我們的臉書專頁

科學支持的最完整的草藥數據庫

  • 支持55種語言
  • 科學支持的草藥療法
  • 通過圖像識別草藥
  • 交互式GPS地圖-在位置標記草藥(即將推出)
  • 閱讀與您的搜索相關的科學出版物
  • 通過藥效搜索藥草
  • 組織您的興趣並及時了解新聞研究,臨床試驗和專利

輸入症狀或疾病,並閱讀可能有用的草藥,輸入草藥並查看其所針對的疾病和症狀。
*所有信息均基於已發表的科學研究

Google Play badgeApp Store badge